<DOC>
	<DOCNO>NCT01009437</DOCNO>
	<brief_summary>RATIONALE : Ritonavir may stop growth tumor cell block enzymes need cancer cell growth . Studying sample blood tissue patient breast cancer laboratory may help doctor learn effect ritonavir biomarkers involve breast cancer growth . PURPOSE : This phase I/II trial study best dose ritonavir effect biomarkers woman undergo surgery newly diagnose breast cancer .</brief_summary>
	<brief_title>Ritonavir Its Effects Biomarkers Women Undergoing Surgery Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect ritonavir Akt activity , UPR , Ki67 LI , ROS triple-negative breast cancer model . - Determine maximum tolerate dose ritonavir woman newly diagnose breast cancer . ( Phase I - enrollment complete ) OUTLINE : This multicenter , phase I dose-escalation study follow phase II study . Control Group - Five patient estrogen receptor positive ( ER+ ) human epidermal growth factor 2 negative ( HER2- ) breast cancer enrol start phase I recruitment . Phase I Group - Twelve breast cancer patient either 1 ) ER+ , HER2- , 2 ) ER+ , HER2+ , 3 ) ER- , HER2+ , 4 ) ER- , PR+ , HER2- , 5 ) ER- , PR- , HER2- enrol dose escalation study . Phase II Group - Nineteen ER+ , HER2- patient enrol ritonavir pharmacokinetic study maximum tolerate dose ( MTD ) establish . - Control : Patients receive ritonavir . - Phases I II : Patients receive oral ritonavir twice daily 5 day absence disease progression unacceptable toxicity . Patients undergo surgery deem appropriate surgeon base patient preference ( mastectomy lumpectomy sentinel node procedure and/or axillary node dissection ) . All patient undergo blood tissue sample collection periodically biomarker research study . Samples patient enrol control group compare sample patient enrolled phase I II .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Inclusion criterion : Newly diagnose biopsy prove breast cancer lumpectomy mastectomy plan . Control Selection ER+ , HER2 : estrogen receptor positive ( ER+ ) human epidermal growth factor receptor 2 negative ( HER2 ) define accord institutional standard . Phase I Selection ER+ , HER2 ER+ , HER2+ ER , HER2+ ER , PR+ , HER2 ER , PR , HER2 Phase II Selection ER+HER2 : define control Menstrual status note either pre postmenopausal . For purpose study , postmenopausal define menstrual period 12 month longer bilateral oophorectomy Sufficient tumor tissue diagnostic core biopsy , either block minimum 5 slide Tumor must great 1 centimeter measure clinical exam , mammogram , ultrasound MRI . No prior treatment breast cancer affect breast . Karnofsky performance status &gt; 70 % No prior treatment breast cancer affect breast Adequate organ function receive study drug within 14 day 1st dose study drug Women childbearing potential require use effective method contraception Voluntary write consent Exclusion criterion : Pregnant lactating . Known positive HIV status medication HIV Diagnosis diabetes due potential problem insulin resistance hyperglycemia Any preexist gastrointestinal complaint include nausea , abdominal pain and/or diarrhea Known hypersensitivity ritonavir tablet ingredient Coadministration ritonavir contraindicate drug Contraindicated Drugs competition primarily CYP3A ritonavir could result inhibition metabolism drug create potential serious and/or lifethreatening reaction cardiac arrhythmia , prolong increase sedation , respiratory depression . Voriconazole exception coadministration ritonavir voriconazole result significant decrease plasma concentration voriconazole . If patient discontinue contraindicate drug , eligible trial . Incompatible Drugs</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>